Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2010 - 2021)

Jazz Pharmaceuticals' Amortization of Deferred Charges history runs 16 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 72.51% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $20.1 million (down 39.12% YoY), while the FY2025 annual figure was $32.5 million, up 48.1% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $4.7 million, down from $5.3 million in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $17.1 million in Q1 2025, with the low at $3.1 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $5.6 million (2022), against an average of $7.0 million.
• The sharpest annual moves came in 2022 and 2025: Amortization of Deferred Charges slumped 77.55% in 2022, then jumped 185.57% in 2025.
• Jazz Pharmaceuticals' Amortization of Deferred Charges stood at $6.0 million in 2022, then advanced by 2.55% to $6.1 million in 2023, then slumped by 49.44% to $3.1 million in 2024, then jumped by 72.13% to $5.3 million in 2025, then slipped by 11.8% to $4.7 million in 2026.
• Business Quant data shows JAZZ's Amortization of Deferred Charges at $4.7 million in Q1 2026, $5.3 million in Q4 2025, and $5.3 million in Q3 2025.